Abstract

As an emerging kind of crystalline material, the metal-organic framework (MOF) has shown great promise in the biomedical domains such as drug storage and delivery. In this study, a new porous MOF, [[Dy2(H2O)3(SDBA)3](DMA)6] (1, H2SDBA = 4,4′-sulfonyldibenzoic acid, DMA = N,N-dimethylacetamide (C4H9NO)), with uncoordinated O donor sites has been fabricated using a bent polycarboxylic acid organic linker under the solvothermal condition. The structure of the obtained crystalline product has been fully determined by the X-ray single-crystal diffraction, TGA, elemental analysis, XRD, and the gas sorption measurement. Due to the suitable window size and polar atom functionalized 1D channels, the activated 1 (1a) compound was used for the anticancer drug 5-fluorouracil (5-Fu, C4H3FN2O2) loading by a simple impregnation method. A moderate drug loading and pH-dependent drug-release behavior could be observed for 1a. Furthermore, as indicated by the MTT assay, this drug/MOF composite shows low toxicity toward the human normal cells and demonstrates obvious anticancer activity against the human osteosarcoma cell line MG63.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.